Amneal Pharmaceuticals, Inc. 4

President & Co-CEO Chirag K. Patel indirectly acquired 6,381,734 shares of Amneal Pharmaceuticals, Inc. Class A Common Stock through limited liability companies as part of the Kashiv BioSciences acquisition consideration.

On August 10, 2026, Amneal Pharmaceuticals, Inc. issued 6,381,734 shares of Class A Common Stock to limited liability companies managed by President & Co-CEO Chirag K. Patel as part of the stock consideration in the company’s $375 million cash plus 28,942,098-share acquisition of Kashiv BioSciences, LLC. The Form 4 reports this as an acquisition of indirectly owned Class A shares, with Mr. Patel’s beneficial ownership now including 6,381,734 shares held through LLCs, 1,393,470 shares held directly, and 21,269,420 shares held indirectly through family trusts. The transaction represents a large, non‑open‑market, deal‑related equity issuance rather than a discretionary purchase or sale by the insider, but it materially increases his indirect equity stake via the acquiring entities.

Filing Facts

CIK

1723128

Ticker

AMRX

Form

4

Source Type

fda

Accession

0001628280-26-056285

Alert Tier

7